A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and…

A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and hospitalization risk by 47.0% compared to Pfizer/BioNTech's BNT162b2 in older veterans during the 2025-2026 season. The study included 294,499 participants, with mRNA-1283 showing better outcomes across various metrics. Moderna supported the study, which was conducted by independent investigators.

Original reporting
Published Nov 20, 2026, 7:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
A study in JAMA Network Open found Moderna's mRNA-1283 vaccine reduced medically attended COVID-19 risk by 35.9% and… — source image
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The findings provide new real-world comparative effectiveness data that could influence investor sentiment toward both vaccine makers.

02

Market read

New comparative effectiveness data could shift market perception of COVID-19 vaccine leaders, impacting stock valuations.

03

What to watch

Study limited to older US veterans; results may not generalize to broader populations.

Relevance 8/10Novelty 9/10Timing: no immediate timing relevance

Background

A JAMA Network Open study compared Moderna's mRNA-1283 vaccine to Pfizer's BNT162b2 in older US veterans, finding a 35.9% lower risk of medically attended COVID-19 and a 47% lower risk of hospitalization for Moderna.

Company-level read

Ticker impact

$MRNABullishMedium confidence
Context

Moderna's mRNA-1283 vaccine showed 35.9% lower risk of medically attended COVID-19 versus Pfizer in the study.

Expected impact

likely upside as data supports superior efficacy

Evidence & confidence

New comparative effectiveness data could improve market perception and drive buying pressure.

$PFEBearishMedium confidence
Context

Pfizer's BNT162b2 vaccine showed higher risk of COVID-19 outcomes compared to Moderna in the same study.

Expected impact

potential downside as study shows lower effectiveness

Evidence & confidence

Study results could raise concerns about Pfizer's vaccine competitiveness, pressuring the stock.

Market effects

COVID-19 vaccine market may shift favoring Moderna's product.

US biotech sector could see revaluation based on efficacy data.

Global vaccine competition dynamics may be affected by the study.

Counterpoint

Pfizer's broader portfolio and other vaccine candidates may offset concerns from this single study.

Key entities

  • Moderna Inc.

    Developer of the mRNA-1283 vaccine.

  • Pfizer Inc.

    Manufacturer of the BNT162b2 (Comirnaty) vaccine.

  • JAMA Network Open

    Journal publishing the comparative effectiveness study.

  • Veterans Health Administration

    Source of the veteran cohort used in the study.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$MRNAMed

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

Moderna's (MRNA) cancer vaccine showed positive Phase 3 results, reducing recurrence or death risk by 42% with Merck's Keytruda, but shares fell 25% as results narrowly missed high expectations. Analysts later noted additional benefits, including a 58% risk reduction after six months and a favorable safety profile. The vaccine's potential extends beyond melanoma, with trials in other cancers ongoing. Despite FDA approval pending, Moderna's high valuation and preliminary data raise concerns.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.